Caris Life Sciences (CAI) Cash from Financing Activities (2024 - 2026)

Caris Life Sciences' Cash from Financing Activities history runs 3 years deep, the most recent figure standing at $824000.0 for Q1 2026.

• In Q1 2026, Cash from Financing Activities fell 35.88% year-over-year to $824000.0; the TTM figure through Mar 2026 stood at $664.5 million (changed N/A YoY), while the FY2025 annual figure was $665.0 million, up 232.01% from the prior year.
• Cash from Financing Activities for Q1 2026 stood at $824000.0, down from $3.4 million in the prior quarter.
• The five-year high for Cash from Financing Activities was $681.4 million in Q2 2025, with the low at -$21.1 million in Q3 2025.
• The 3-year median for Cash from Financing Activities is $824000.0 (2026), against an average of $95.2 million.
• Peak annual rise in Cash from Financing Activities reached 1403.98% in 2025, while the deepest fall reached 24349.43% in 2025.
• Caris Life Sciences' Cash from Financing Activities stood at $226000.0 in 2024, then jumped by 1403.98% to $3.4 million in 2025, then tumbled by 75.76% to $824000.0 in 2026.
• Business Quant data shows CAI's Cash from Financing Activities at $824000.0 in Q1 2026, $3.4 million in Q4 2025, and -$21.1 million in Q3 2025.